Weight-loss stocks soar up to 15% after obesity-drug study shows an added benefit that may be a 'huge win' for future sales

Novo’s Wegovy showed a 20% reduction in heart issues compared to those getting a placebo in a closely watched study.

Posted from: this blog via Microsoft Power Automate.